Building a Pipeline
of Immunotherapies

Gritstone is building a pipeline of immunotherapy product candidates for patients with solid tumors. Our first patient-specific neoantigen immunotherapy product candidate, GRANITE-001, will initially be evaluated in the treatment of common solid tumors, including metastatic non-small cell lung cancer and gastroesophageal, bladder and colorectal cancers, in each case in combination with checkpoint inhibitors. In the second half of 2018, we intend to submit our Investigational New Drug application for GRANITE-001 and, upon acceptance, to initiate a first-in-human Phase 1/2 trial in combination with checkpoint inhibitors.

Our second tumor-specific product candidate, SLATE-001, will utilize the same antigen delivery system as GRANITE-001 but contains a fixed set of neoantigens that are shared across a subset of cancer patients rather than neoantigens unique to an individual patient, providing us with an off-the-shelf alternative to GRANITE-001. We also expect to investigate clinical combinations of future SLATE product candidates with immune checkpoint inhibitors and are expecting to enter human clinical trials for SLATE-001 in the second half of 2019.

Gritstone is also leveraging EDGE™ as a unique antigen discovery platform to define targets for other immunotherapies such as T-cell receptor (TCR) directed cell therapies and bispecific antibody therapies. These additional targets that were identified and validated by EDGE™ enable us to partner with others or develop additional therapeutic approaches to redirect T cells onto tumors using these highly specific targets.

an Impact

We are committed to progressing the field of immunotherapy, with a goal to eradicate cancer by initially developing personalized immunotherapies that focus on the unique and individual nature of a patient’s tumor. Our dynamic team combines novel science with focus on team work, and we are looking for passionate, innovative people to join us.